{"id":"NCT05301322","sponsor":"Pfizer","briefTitle":"Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age","officialTitle":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE IN ADULTS ≥65 YEARS OF AGE","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-04-13","primaryCompletion":"2022-10-12","completion":"2022-10-12","firstPosted":"2022-03-29","resultsPosted":"2023-10-27","lastUpdate":"2023-10-27"},"enrollment":1471,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Respiratory Syncytial Virus"],"interventions":[{"type":"BIOLOGICAL","name":"RSVpreF Vaccine","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]},{"type":"BIOLOGICAL","name":"Seasonal Inactivated Influenza Vaccine","otherNames":[]}],"arms":[{"label":"Coadministration Group","type":"EXPERIMENTAL"},{"label":"Sequential Administration Group","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the safety and immunogenicity of RSVpreF when coadministered with SIIV compared to sequential administration of the vaccines when given 1 month apart (SIIV followed by RSVpreF). Additionally, the study will contribute data supporting the development of RSVpreF as a prophylactic vaccine against RSV disease in infants through maternal immunization and in older adults through active vaccination.","primaryOutcome":{"measure":"Percentage of Participants Reporting Local Reactions Within 7 Days After Vaccination With RSVpreF or Placebo","timeFrame":"Within 7 days after Vaccination 1 or Vaccination 2","effectByArm":[{"arm":"RSVpreF + SIIV: Coadministration Group","deltaMin":10.1,"sd":null},{"arm":"Placebo: Coadministration Group","deltaMin":6.5,"sd":null},{"arm":"Placebo + SIIV: Sequential-Administration Group","deltaMin":7.6,"sd":null},{"arm":"RSVpreF: Sequential-Administration Group","deltaMin":11.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"65 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":33,"countries":["Australia"]},"refs":{"pmids":["37992000"],"seeAlso":["https://pmiform.com/clinical-trial-info-request?StudyID=C3671006"]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":703},"commonTop":["Fatigue (FATIGUE)","Headache (HEADACHE)","Myalgia (MUSCLE PAIN)","Injection site pain (PAIN AT INJECTION SITE)","Arthralgia (JOINT PAIN)"]}}